EP2145017A2 - Procédé de détection et/ou d'isolement de mycobactéries - Google Patents
Procédé de détection et/ou d'isolement de mycobactériesInfo
- Publication number
- EP2145017A2 EP2145017A2 EP08750988A EP08750988A EP2145017A2 EP 2145017 A2 EP2145017 A2 EP 2145017A2 EP 08750988 A EP08750988 A EP 08750988A EP 08750988 A EP08750988 A EP 08750988A EP 2145017 A2 EP2145017 A2 EP 2145017A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- mycobacteria
- sample
- seq
- pcr
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/02—Separating microorganisms from their culture media
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
- G01N33/5434—Magnetic particles using magnetic particle immunoreagent carriers which constitute new materials per se
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
Definitions
- the present invention relates to the field of mycobacteria and more specifically to a method for efficient and selective isolation of mycobacteria strains. Subsequent to the isolation of the mycobacteria strains, detection, quantification and identification of these strains can be performed.
- the method of the invention may be applied to non-tuberculosis mycobacteria (NTM).
- Mycobacteria are gram positive bacteria with a very slow-growth rate. On solid culture, the growth rate goes up to 30 days. Besides the tuberculosis causing bacteria from the M. tuberculosis-comp ⁇ ex, or the paratuberculosis causing M. aww/77-complex and M. leprae, the so-called environmental bacteria (EM) are saprophytic, aquatic bacteria with a human pathogenicity. Recent examinations found them to be present in a wide variety of water-samples such as in drinking water and in biofilms of water distribution systems (LeDantec C et al., 2002; Vaerewijck MJ et al., 2005).
- EM environmental bacteria
- the concentration of bacteria with para-magnetic beads is used regularly in microbiological applications, but most of the studies published thus far are not driven by the interest to capture very low amounts of bacteria, since, in most of the cases, a pre-amplification phase is included or the initial number of bacteria in the sample is already very high (> 1000 cfu/ml).
- Examples of a few of these published studies include the immunomagnetic isolation method described in Fu et al. (2005) which exhibits an efficiency of 50% on E.coli and therefore allows for the recovery of 50% of the bacteria present in the sample. Similarly, the same efficiency is observed for the immunomagnetic isolation method on Campylobacter jejuni (Yu et al., 2005). Grant et al. (2000) deal with the isolation of M. avium from milk. The process disclosed in Grant et al. (IMS- PCR) only has a sensitivity of 20 cfu/ml or 20,000 cfu/L.
- An object of the present invention is to provide a method for isolating Mycobacteria strains.
- this object is achieved with a method for isolating mycobacteria from a sample, the method comprising the steps of: a) contacting a sample suspected of containing mycobacteria with magnetic beads coated with an antibody immunologically specific to mycobacteria under three-dimensional motion conditions to form bead-mycobacteria complexes, and b) magnetically recovering the bead-mycobacteria complexes to obtain a sample containing isolated mycobacteria strains.
- Another object of the present invention is achieved with a method for detecting mycobacteria from a sample, the method comprising the steps of: a) contacting a sample suspected of containing mycobacteria with magnetic beads coated with an antibody immunologically specific to mycobacteria under three-dimensional motion conditions to form bead- mycobacteria complexes; b) magnetically recovering the bead-mycobacteria complexes to obtain a sample containing isolated mycobacteria strains; and c) determining the presence or absence of the defined mycobacterium strain by the detection of said defined mycobacterium strain.
- a further object of the present invention is achieved with a method for detecting viable mycobacteria from a sample, the method comprising the steps of: a) contacting a sample suspected of containing mycobacteria with magnetic beads coated with an antibody immunologically specific to mycobacteria under three-dimensional motion conditions to form bead- mycobacteria complexes; b) magnetically recovering the bead-mycobacteria complexes to obtain a sample containing isolated mycobacteria; c) adding a viability determining agent to the sample containing isolated mycobacteria; d) extracting genomic DNA from the sample containing isolated mycobacteria of step c); and e) detecting the genomic DNA of a defined mycobacterium strain; wherein the detection of a predetermined number of mycobacteria genomes of the defined mycobacterium strain is indicative of a viable mycobacterium strain.
- the methods of the present invention advantageously provide a way for isolating and concentrating small quantities of mycobacteria from a sample of any given size. It also avoids the culture of the sample in order to obtain a sufficient concentration of bacteria in order to proceed with the detection thereof. Another advantage is that the method of the present invention yields a good quality DNA for further analysis and quantification.
- Figure 1 Estimation of the capture efficiency (%) of different types of immuno-magnetic capture beads.
- the beads used in the assays were treated as follows: 2.8 ⁇ m BSA coated: 100 ⁇ L tosylactivated magnetic beads 2.8 ⁇ m (Dynal) were incubated with 100 ⁇ l BSA in IxPBS (1mg/ml) over night at 37°C on a horizontal rotary shaker and washed with 0.2M Tris-buffer pH 8.0. 4.5 ⁇ m-lgG-35111 and 2.8 ⁇ m-lgG- 35111: The polyclonal antiserum 35111 was purified through a ProteinA- column.
- tosylactivated beads in the two respective sizes were incubated overnight at 37°C with the derived IgG-fraction from 35111 (1mg/ml in 0.1 M phosphate buffer) and washed in 0.2M Tris pH 8.0 to block remaining active sites on the bead-surface.
- 2.8 ⁇ M-ProtA-lgG-35111 2.8 ⁇ m tosylactivated beads were incubated with recombinant ProteinA (1mg/ml in 0.1 M phosphate buffer, Sigma) at 37°C and washed with 0.2M Tris pH 8.0.
- the ProteinA coated beads were incubated for 1 h at room-temperature with the IgG-fraction of 35111 (1mg/ml in IxPBS).
- 4.5 ⁇ m-lgG-affinity 4.5 ⁇ m tosylactivated beads (Dynal) were incubated with an affinity-purified fraction of 35111-IgG purified for their affinity against Mycobacterial surface-proteins.
- Figure 2 Capture efficiency (%) as a function of bacterial concentration using 2.8 ⁇ M-ProtA-lgG-35111 -beads.
- the given capture efficiency for a "low" number of bacteria (5.10 3 (5E03)) is below 25% while a high number of bacteria present results in a capture efficiency of above 75%. It is shown that the use of a two- dimensional incubation on a rocking platform in combination with a small sample volumen (500 ⁇ l) as used in other approaches for the immunomagnetic bead concentration is not satisfying to ensure an efficient capture of low bacterial concentrations.
- Figure 3 Capture-efficiency as dependent on sample volume.
- M. abscessus bacteria were captured with 100 ⁇ l (2*10 8 beads) of 2.8 ⁇ M-ProtA-lgG-35111 beads. Capture efficiency was estimated through plate culture. The incubation during 30 minutes at room-temperature was performed using a 360° rotary shaker with the tubes fixed orthogonally as indicated in Figure 11.
- Figure 3 shows that through the use of three- dimensional incubation from a volume of 500 ⁇ l, the capture efficiency of a comparable number of CFU in the test (5.10 5 (5E05) ( Figure 2) and 1.10 5 (1 E05) ( Figure 3) is already 2.5-fold higher (48% for the 2-dimensional incubation and 65% for the three-dimensional incubation).
- the recommended ratio of bead number (2.10 8 beads (2XE08 beads)) and assay volume (500 ⁇ l) as recommended by Dynal) is not efficient.
- Using a 10-fold larger assay volume (5000 ⁇ l) together with the same number of beads (2.10 8 (2XE08)) the capture efficiency was over 75%.
- FIG. 5A and 5B Photograph of the agarose gel for gene-specific PCR for Mycobacteria that have been concentrated (Fig 5A) and immuno- captured (Fig. 5B) showing that bead capture increases the detection sensitivity in water-samples. 200ml of water were spiked with the indicated numbers of M. abscessus.
- smclll is a tap-water sample with a bacterial load of 1.1O 3 cfu (1 E03 cfu) Mycobacteria.
- Figure 6 Schema of test-procedure for Mycobacteria in water-samples.
- Step 1 Water-samples are concentrated non-specifically through filtration on a 0.45 ⁇ m polycarbonate membrane (Step 1).
- the total bacteria present on the filter are detached in 5ml capture-buffer through intensive vortexing for 15 minutes (Step 2).
- the solubilised bacteria are specifically coated through antibody- coated paramagnetic beads (Step 3).
- the genomic DNA from the bead- captured Mycobacteria is prepared through a developed protocol (Step 4).
- the prepared DNA serves as template for a Mycobacteria genus-specific PCR inside the hsp65-gene (Step 5).
- Figure 7 Course of immunisations of rabbits with Mycobacterial cell wall preparations and the estimation of the serum titers against their antigen.
- Rabbits were immunised through injections with native cell wall-preparations of the following Mycobacterial species: M. kansasii, M. xenopi, M. avium, M. abscessus and M. gordonae.
- 500 ⁇ l lysate (1mg/ml) was mixed with 500 ⁇ l of incomplete Freund's Adjuvant and injected subcutaneously at five different locations on the rabbit. Each antigen was injected into two different rabbits. Ten days after the immunisation, 5 ml of blood were collected. An ELISA test was used to estimate the serum titer. An immunisation was regarded as successful when a titer above 1.10 4 (1 E04) was reached.
- Figures 8A to 8D Estimation of the sera cross-reactivity against the different Mycobacterial antigens. ELISA-plates were coated with membrane preparations from six different Mycobacterial species as indicated. For each serum the titer of response to the different antigens was estimated. Note the broad cross-reactivity of serum 35111 (Figure 8B) and the strong reactivity of 36147 against its designated antigen M. xenopi ( Figure 8C). Serum 36040 shows a five-fold higher reactivity against its antigen M. avium ( Figure 8D). M. gordonae (Figure 8A) is specifically recognised by the developed antiserum 37174.
- Figures 9A to 9E Quantification of Mycobacterial charge through realtime PCR. Genomic DNA prepared from M. abscessus was diluted in consecutive steps down to a concentration of 1pg/ ⁇ l. The template DNA was added to a Sybergreen-based MasterMix. Real-time PCR with the primer-combination tb11-12 (SEQ ID NO:1 and SEQ ID NO:2) amplified a sequence from the hsp65 gene.
- Figure 9A shows the development of the fluorescence signals in dependence of the cycle number
- Figure 9B shows the linearity of the amplification reaction over a range of 1.10 3 pg (1 E03 pg) down to 1 pg genomic DNA, the equivalent of 200 mycobacterial genomes.
- Figures 9C and 9D shows the analysis of a quantitative assay of water-samples spiked with different dilutions of M .abscessus. The assay was performed as indicated in Figure 6. The assay detected bacterial concentrations down to 1.5.10 3 cfu (1.5E03 cfu) ( Figure 9C). Note the linearity of the assay is not given for low amounts of bacteria ( Figure 9D).
- Figure 9E shows the agarose gel of the quantitative PCR showing the formation of primer-dimers, when amplifying low amounts of template DNA.
- Figures 1OA and 1OB Molecular Live/Dead assay for Mycobacteria using Propidium-Monoazide (PMA)
- Dead and live Mycobacteria (standardised on McF 1) were mixed in 6 different ratios (0%, 10%, 25%, 50%, 80% and 100% living bacteria) in 1ml samples.
- the samples were divided into two fractions: 1) incubation at room temperature for 20 min (-PMA); 2) incubation with PMA 50 ⁇ M end concentration for 20 min at room temperature in the dark (+PMA). After the incubation, both samples were illuminated for 2 minutes with 650W on ice.
- the genomic DNA of both fractions (-PMA and +PMA) was isolated.
- Figure 10A shows the quantitative analysis of the DNA amount through real-time PCR.
- FIG. 10B shows the percentage of DNA isolated after PMA treatment vs percentage of living bacteria in sample; DNA is measured by spectroscopic analysis at 260 nm of the isolated DNA from both samples (Nanotrop apparatus).
- Figure 11 Schema showing the position of the sample tube during incubation for immunomagnetic bead capture.
- the pre-concentrated sample is transferred into 5ml of IxPBS supplemented with 0.1% Tween20.
- the 15 ml polystyrene tube is fixed in 45° angle from the rotor using a 2 cm distance from the axe of the rotor.
- the optimal turning speed to prevent sedimentation of the beads and not to disturb the fragile bead-bacteria connection was shown to be 2 rpm.
- the incubation was performed at room-temperature during a time spin of 30 minutes using an ELMI-lntelli Mixer RM2TM.
- the bacteria-charged beads were captured with a magnetic bead retriever (Dynal), the supernatant was aspirated.
- the beads were washed through a 2-fold incubation with IxPBS supplemented with 0.1% Tween20 for 5 minutes.
- the bead-bacteria complexes were transferred in a buffer adapted in the down-stream applications.
- Figure 12 Photograph of the agarose gel of the sodA PCR-reaction following the sodA qPCR assay. Based on a list of Mycobacterial housekeeping-genes (Department of Biochemistry and molecular biology, Oswaldo Cruz, Rio de Janeiro, Brasil) (http://www.dbbm.fiocruz.br/genome/mycobac/tubhousekeep.html), the inventors searched for available sequence information from non tuberculosis Mycobacteria (NTM) with emphasis on the NTM found in water (M .kansasii, M. gordonae, M. xenopi, M. abscessus, M.
- NTM non tuberculosis Mycobacteria
- the chosen assay amplifies a 150bp variable stretch surrounded by two highly conserved regions (Position 484-510 and 670-700 on the M. avium superoxide dismutase A-gene (sodA; EMBL AccNr. AF180816; LJu 1 X.; Feng.Z.; Harris.N.B.; Cirillo.J.D.; Bercovier.H.; Barletta.R.G.; Identification of a secreted superoxide dismutase in Mycobacterium avium ssp. paratuberculosis FEMS Microbiol. Lett. 202(2):233-238 (2001)).
- the chosen primer pair sod-f (SEQ ID NO:11) and sod-r (SEQ ID NO:12) was used in a standard PCR reaction (50 ⁇ l-assay volume primer end concentration
- the photo shows the results of the PCR-reaction, sod-f-sod-r, on a series of consecutive genomic DNA dilutions 10 ng/ ⁇ l to 100pg/ ⁇ l from five different
- Mycobacteria resolved on a 1.5% agarose-gel. Note the absence of visible primer-dimers on the gel also at low DNA-concentrations.
- Figure 13 Evaluation of the specifity of the sodA-qPCR assay.
- the PCR reaction contained a 5 minute activation phase at 95°C, the amplification was performed as follows: 15sec at 95°C, 15sec at 56°C and polymerisation for 30 sec at 72°C.
- the specificity of the amplicon was estimated through a melting curve analysis.
- the assay included a negative contamination control consisting of PCR-grade water treated in the same manner as the samples. Each sample was performed in a duplicate qPCR- reaction.
- the analysis of the data was performed through the Roche Lightcycler software. Ct-values, slope and PCR efficiency were estimated using the second derivative maximum method. Note the efficiency of the qPCR reaction (slope of the calculated lines) is equivalent for all the species tested.
- the estimated PCR-efficiency (slope of the calculated lines) of the sodA qPCR with genomic DNA templates is the same for all tested mycobacterial species.
- Figure 14 Reliability of the sodA qPCR assay
- Prepared genomic DNA from M. abscessus in a concentration of 1 ng/ ⁇ l was diluted in 12 independent assays consecutively down to 0.1pg/ ⁇ l. 2 ⁇ l of each dilution was used as template in the qPCR assay targeting the sodA gene as described in Figure 13.
- the estimated ct-values were transformed into DNA- concentrations using the absolute quantification module of the Lightcycler software. Linear fitting, calculation of the r 2 and P-value were performed using the lnStatTM-software (Graph-Pad, USA).
- Figure 15 lmmunocapture qPCR with spiked water samples
- the assay was also performed on a genomic DNA-dilution also transformed into genomes per assay (0). Note that the loss of genomes through immunocapture is related to the initial concentration of bacteria in the spike: high concentrations resulted in 90% of the spiked bacterial DNA recovered, while the recovery for low concentrations of initial bacteria (>100 bacteria) drops to an average of 40%.
- Figure 16 Calculation of the mycobacterial charge in a spiked water sample with immunocapture qPCR
- Figure 16 shows the calculated 95% confidence interval for the genome number calculation from spiked 1 liter water samples with the immunocapture PCR.
- the correlation is linear over a range from 100 to 1.10 7 (1E02 to 1 E07) genomes/ liter water.
- the absolute limit of quantification is 100 genomes per liter water, while the analytical sensitivity is below 10 genomes. Due to the losses of bacteria during sample treatment, the real bacterial charge expressed in genomes per liter is underestimated up to 50% depending on the initial bacterial concentration.
- mycobacterial content of 1 liter water samples was preconcentrated and immunocaptured as indicated in the protocol of Example 2. After genomic DNA preparation the mycobacterial charge was quantified with the sodA qPCR assay. For a further characterisation of the pathogenic potential, mycobacterial species could be directly identified from samples with an estimated mycobacterial genome number above 1000 (Par5, Iss, PaM 4, Drin bef) ( Figure 18).
- the mycobacterial genomic DNA from samples with an estimated mycobacterial charge over 1000 genomes as estimated in Figure 17 was used as a template in a hsp65 PCR reaction (Telenti, AF et al., 1993). Mycobacterial species could be directly identified from samples with estimated mycobacterial genome numbers above 1000 (Par5, Iss, Par14, Drin bef) ( Figure 17).
- the obtained PCR product was digested in two separate reactions with the restriction enzymes Haelll and BestEII.
- Figures 18A and 18B show the obtained restriction patterns resolved on a 5% agarose gel. The fragment lengths were estimated with the program Quantity OneTM (BioRad, USA).
- Figure 19 staining and microscopy displaying of Mycobacteria after bead-capture
- sample may be a liquid sample.
- a liquid sample may be, but is not limited to, a water, milk or sputum sample.
- a water sample may include an environmental water sample as tap water or untreated water sample.
- the liquid sample may also include a biofilm sample, wherein the biofilm is understood by a person skilled in the art as being a complex aggregation of microorganisms marked by the excretion of a protective and adhesive matrix often found on the surface of water in water treatment systems.
- the sample may contain one or a plurality of mycobacteria strains amongst other types of bacteria or contaminants found in tap water or in untreated water.
- a "mycobacterium strain” may be any type of mycobacteria such as a non-tuberculosis mycobacterium (NTM).
- NTM non-tuberculosis mycobacterium
- a non-exhaustive list of NTM strains detected by the method of the invention may be : M. abscessus, M. kansasii, M. xenopi, M. avium and M. gordonae.
- NTM strains such as those listed as part of Table 3
- the term "detecting” refers to the identification of a component of a microorganism, such as an epitope or a particular nucleotide sequence, which thereby determines the presence of the microorganism. It will be further understood that any one strain from the plurality of mycobacteria strains in the sample may be detected independently of any other strain. Also, it will be understood that more than one strain from the plurality of mycobacteria strains can be advantageously detected at the same time, and such, independently of any other strains. The term “detecting” can also refer to staining and microscopy visualisation of mycobacteria.
- the expression "defined mycobacterium strain” denotes the mycobacterium strain that the method is tailored to detect, insofar as the method may be tailored to detect as many mycobacterium strains as possible from the sample, either specifically or non-specifically, independently of one another, or may be tailored to detect a single mycobacterium strain.
- low concentration of mycobacteria is understood to be measured as a Mycobacterial charge under 1000 mycobacterial genomes in 1 liter of water as estimated via qPCR.
- a viability determining agent refers to an agent that selectively allows the determination of whether a cell is dead or alive (viable). More particularly, such an agent may penetrate cells which can be considered dead and therefore may inhibit its nucleic acid amplification for determining its viability.
- a contemplated viability determining agent by the present invention may be a membrane-impermeant dye (e.g. propridium mono-azide (PMA)) that selectively penetrates cells with compromised membranes, such cells being considered dead.
- PMA propridium mono-azide
- a predetermined number of mycobacteria genomes is indicative of a viable mycobacterium strain refers to a defined number of genomes associated with a specific mycobacterium strain. In general, about 1000 or more mycobacteria genomes will be an indication that a sample contains viable mycobacteria strains. For instance, in the experiments performed with locally obtained water (Region lie de France) (see Example section) no Mycobacteria were grown on solid culture from samples with an estimated mycobacterial charge under 1000 genomes per liter.
- the term “specific” or “immunologically specific” or “specifically directed” means that it is characteristic of the antibody to possess substantially greater affinity for mycobacteria than for other microorganisms contemplated by the present invention.
- the inventors have developed and optimised a method for selectively isolating Mycobacteria strains from a sample.
- the method is advantageously based on the non-specific and specific isolation of Mycobacteria present in a sample.
- the invention provides methods for the selective isolation and/or detection of mycobacteria from a sample.
- an embodiment of the present invention is to provide a method for isolating mycobacteria from a sample which comprises a step a) of contacting a sample suspected of containing mycobacteria with magnetic beads coated with an antibody immunologically specific to mycobacteria under three- dimensional motion conditions to form bead -mycobacteria complexes.
- a preferred embodiment of the present invention is to provide a method for isolating a NTM strain from a sample which comprises a step a) of contacting a sample suspected of containing a NTM strain with magnetic beads coated with an antibody immunologically specific to the NTM strain under three- dimensional motion conditions to form bead-NTM complexes.
- an optional non-specific filtering step so as to provide a concentrate of the sample.
- Such optional step may be achieved by a filter that allows the retention of mycobacteria (e.g. NTM strains), such as a 0.45 ⁇ m filter.
- This optional filtration step may be followed by a resuspension step of the bacteria stuck on the filter in a small volume (e.g. 5 ml) of buffer.
- a small volume may thereafter be used as a starting sample for the isolating method of the present invention.
- the buffer in which the bacteria or concentrate are resuspended may be any buffer suitable to be used in accordance with the isolating and/or detecting methods of the invention
- the volume of the starting sample is comprised between 0.5 and 25 ml, preferably comprised between > 0.5 and 25 ml and more preferably 5 ml.
- a volume of 0.5 ml may be used with the three dimensional motion conditions.
- step a homogenization and decontamination of sputum sample could be performed.
- the method of Kubica Korean health mycobacteriology: a guide for the level III laboratory, p. 57-68.
- the term “coated” refers to having a coating material, such as an antibody specific for Mycobacteria, on the beads.
- the coating material may totally or partially cover the bead.
- three-dimensional motion conditions refers to the conditions that will allow the sample to be mixed or shaken in about all possible directions at slow tilt rotation, preferably 1-20 rpm, more preferably 2 rpm. Such conditions may be achieved, for instance, by placing the sample into a tube fixed orthogonally on a 360° rotary shaker, as shown in Figure 11.
- the sample is mixed or shaken for a defined period of time so as to permit the bead-mycobacteria complexes to form.
- the expression "for a defined period of time” refers to the time necessary to let the mycobacteria cells to adhere to the beads. It must be at least 2 min and preferably about 30 min; however, it may also be a few hours or even overnight, if convenient.
- the isolating method of the invention also comprises a step b) of magnetically recovering the bead-mycobacteria complexes to obtain a sample containing isolated mycobactehum strains.
- magnetically recovering consists of capturing or retrieving the bead-mycobacteria complexes so as to obtain a sample containing isolated mycobacteria strains.
- the recovery of the complexes may be accomplished with a magnetic bead retriever, or with a magnetic stand as described in Example 2 and Figure 6.
- one skilled in the art may wish to subsequently wash the beads to eliminate components which could be non-specifically fixed to beads.
- gentle washings may be performed by using, for instance, a solution of 1XPBS supplemented with 0.1% Tween20.
- Another optional step further to the step of recovering the bead-mycobacteria complexes, consists of separating mycobacteria from the beads. Such a step may be achieved by strong shaking (e.g. vortexing) of the sample.
- a step of detecting the presence or absence of at least one mycobacterium strain e.g. NTM strain
- the method according to this embodiment of the present invention can further comprise, after step b), a step of detecting the presence or absence of a mycobacterium strain from the sample containing isolated mycobacterium strains.
- Another embodiment of the present invention relates to a method for detecting mycobacteria comprising the steps of: a) contacting a sample suspected of containing mycobacteria with magnetic beads coated with an antibody immunologically specific to mycobacteria under three-dimensional motion conditions to form bead- mycobacteria complexes; b) magnetically recovering the bead-mycobacteria complexes to obtain a sample containing isolated mycobacteria strains; and c) determining the presence or absence of a defined mycobacterium strain by the detection of said defined mycobacterium strain.
- Another preferred embodiment of the present invention relates to a method for detecting NTM comprising the steps of: a) contacting a sample suspected of containing a NTM strain with magnetic beads coated with an antibody immunologically specific to NTM under three-dimensional motion conditions to form bead-NTM complexes; b) magnetically recovering the bead-NTM complexes to obtain a sample containing isolated NTM strains; and c) determining the presence or absence of a defined NTM strain by the detection of said defined NTM strain.
- a downstream analysis can be performed to estimate the proportion of dead bacteria and live bacteria in the concentrated bacteria sample.
- a method for detecting viable mycobacteria comprises the steps of: a) contacting a sample suspected of containing mycobacteria with magnetic beads coated with an antibody immunologically specific to mycobacteria under three-dimensional motion conditions to form bead- mycobacteria complexes; b) magnetically recovering the bead-mycobacteria complexes to obtain a sample containing isolated mycobacteria; c) adding a viability determining agent to the sample containing isolated mycobacteria; d) extracting genomic DNA from the sample containing isolated mycobacteria of step c); and e) detecting the genomic DNA of a defined mycobacterium; wherein the detection of a predetermined number of mycobacteria genomes is indicative of a viable mycobacterium.
- the presence or absence of mycobacteria strains may also be determined by the culture of the mycobacteria concentrated sample, for instance, onto Petri dish.
- the presence or absence of mycobacteria may also be determined by fluorescent staining and/or microscopy observation of the mycobacteria captured on the beads.
- step a one may wish prior to step a), to perform an optional step of filtering the sample non-specifically in order to concentrate the sample.
- This optional filtration step may also be followed by a resuspension step of the bacteria stuck on the filter in a small volume (e.g. 5 ml) of buffer.
- a small volume e.g. 5 ml
- the buffer in which the concentrate or bacteria are resuspended may be any buffer suitable to be used in accordance with the isolating and/or detecting methods of the invention.
- such a buffer may be 1XPBS supplemented with 0.1%
- the step of detecting mycobacteria and particularly NTM strains in a sample can be achieved by immuno detection.
- the immuno detection can be by an enzyme- linked immunosorbent assay (ELISA) or by any other immuno detection method known to one skilled in the art.
- ELISA enzyme- linked immunosorbent assay
- the step of detecting may be achieved by molecular DNA detection which may consist of DNA amplification (e.g. PCR), of nucleic acid hybridization (e.g. Southern blot) or of any other method known by a person skilled in the art.
- molecular DNA detection may consist of DNA amplification (e.g. PCR), of nucleic acid hybridization (e.g. Southern blot) or of any other method known by a person skilled in the art.
- DNA amplification e.g. PCR
- hybridization e.g. Southern Blot
- This coupling will allow the evaluation of the total quantity of mycobacteria in the analyzed sample and the determination of the presence of one or more specific mycobacteria or NTM strains, depending on the probes used.
- a nucleic acid probe is chosen that is complementary to a target nucleic acid sequence, (e.g. a NTM) and then by selection of appropriate conditions the probe and the target sequence "selectively hybridize," or bind, to each other to form a hybrid molecule.
- a nucleic acid probe that is capable of hybridizing selectively to a target sequence under "moderately stringent” conditions typically hybridizes under conditions that allow detection of a target nucleic acid sequence of at least about 15-25 nucleotides in length having at least approximately 70% sequence identity with the sequence of the selected nucleic acid probe.
- Stringent hybridization conditions typically allow detection of target nucleic acid sequences of at least about 15-25 nucleotides in length having a sequence identity of greater than about 90-95% with the sequence of the selected nucleic acid probe.
- Hybridization conditions useful for probe/target hybridization where the probe and target have a specific degree of sequence identity can be determined as is known in the art (see, for example, Nucleic Acid Hybridization: A Practical Approach, editors B. D. Hames and S. J. Higgins, (1985) Oxford; Washington, D.C.; IRL Press).
- Primers or probes used in accordance with the molecular DNA detection contemplated by the present invention are those that are specific to all mycobacteria strains.
- the contemplated primers or probes are those that are specific to all NTM strains.
- the primers or probes can be selected in a nucleotide sequence of NTM genes encoding heat shock proteins (e.g. HSP65).
- HSP65 heat shock proteins
- Tb11f 5'-ACCAACGATGGTGTGT-3 • (SEQ ID NO :1), melting temperature (TM) : 60 0 C 190,9 ⁇ M
- Tb12r 5 > -CTTGTCGAACCGCATA-3 • (SEQ ID NO:2)
- HSPF3 ⁇ '-ATCGCCAAGGAGATCGAGCT-S' (SEQ ID NO: 3), TM 6O 0 C
- HSPR4 ⁇ '-AAGGTGCCGCGGATCTTGTT-S' (SEQ ID NO: 4), TM 60 0 C and hspSHf: ⁇ '-CTGGTCAAGGAAGGTCTGCG-S' (SEQ ID NO: 5) hspSHr: ⁇ '-GATGACACCCTCGTTGCCAAC-S' (SEQ ID NO: 6);
- primers or probes may be produced in order to be used in accordance with the present invention.
- the present inventors have designed and produced primers which can also be used as primers in accordance with the present invention.
- Those primers or probes have been selected in a nucleotide sequence of NTM genes encoding housekeeping genes.
- the housekeeping genes targeted may be selected from the group of genes including, for example, the DNA gyrase B gene (gyrB); the super oxide dismutase gene (sodA), and the NADH-dependent enoyl-acyl-carrier-protein reductase gene (inhA).
- the pairs of primers designed from these genes by the inventors include the following: Primers based on the gyrB gene: gyrB-f 5-TTCGCCAACACCATCAACAC-3 (SEQ ID NO: 7) gyrB-r 5-GTGTTGCCCAACTTGGTCTT-3 (SEQ ID NO: 8);
- sodA-f 5-CCACTCGATCTGGTGGAA-3 (SEQ ID NO: 11) sodA-r 5-TGGTCGTACAGCTGGAAGGT-3 (SEQ ID NO: 12)
- the genome number of at least one mycobacterium strain (e.g. NTM strain) in the sample containing isolated mycobacteria can be estimated.
- the genome number can be estimated by DNA amplification, e.g. by quantitative PCR (qPCR).
- the beads used in accordance with the method of the present invention can have a diameter of about 2 to about 5 microns, and advantageously, of about 2.8 microns.
- Such beads may be hydrophobic beads with p-toluenesulphonyl (tosyl) reactive groups on their surface, such as those described in the Example section hereinbelow.
- the antibody used may be linked to the bead via a linker.
- linker refers to a molecule that acts as an intermediary molecule in the sequestering of the anti-mycobacteria antibody to the bead's surface.
- the linker is attached (e.g. covalently) to the bead's surface and interacts (e.g. non-covalently) with the anti-mycobacteria antibody to maintain such antibody at the surface of the bead.
- a linker which may be used in accordance with the present invention consists of Protein A or of an antibody that can bind the anti-mycobacteria antibody contemplated by the present invention.
- Other commonly used linkers for the coating of beads with antibodies such as a rabbit anti-lgG antibody or Protein G for example, can be used in the method of invention.
- the choice of the linker depends on the animal from which the anti-lgG antibody is obtained.
- the contemplated antibody used in accordance with the present invention may be a polyclonal antiserum or a fraction thereof which has an affinity profile to specifically bind to the majority or all the mycobacteria strains in a sample.
- a fraction may be, for instance the IgG fraction from a polyclonal antiserum raised against a mycobacterium strain.
- a preferred antibody used in accordance with the present invention is a polyclonal antibody which is able to recognize all mycobacteria strains (of M. tuberculosis complex and NTM) with an equivalent specificity.
- a contemplated antibody used in accordance with the present invention may be the 35 111 polyclonal antibody obtained by immunisation of rabbits with lyophilised M.abscessus cell wall preparations and able to recognize all mycobacteria strains with the same affinity as shown in Figure 8B.
- a monoclonal antibody that specifically binds to a mycobacterium strain can also be used to coat magnetic beads in accordance with the present invention.
- the term "monoclonal antibody” means an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts.
- the "monoclonal antibodies” also include clones of antigen-recognition and binding-site containing antibody fragments (Fv clones) isolated from phage antibody libraries using the techniques described in Clackson et al., Nature, 352:624-628 (1991) and Marks et al., J. MoI. Biol., 222:581-597 (1991), for example.
- an antiserum with a higher affinity for a specific strain may wish, in a case where the isolation and/or detection of a target mycobacterium strain (e.g. NTM strain) are of particular interest, to use an antibody specific to such a mycobacterium strain (e.g. a NTM strain).
- a target mycobacterium strain e.g. NTM strain
- an antibody which has the capacity of detecting all mycobacterium strains e.g. all NTM strains
- the present invention consists in an evaluation of different parameters for a magnetic bead capture of mycobacteria. After an optimisation of various parameters, the inventors have shown and presented in the Examples herein below that it is possible to capture even very low amounts of bacteria with a high efficiency (over 75%). This result has not been reached in prior art assays. 5) Further advantages of the present invention
- the isolation method of the invention permits to remove inhibitors of PCR that are in mycobacteria preparations obtained by traditional isolation process consisting in centrifuging sample and recovering a mycobacteria pellet. Then, the isolation method of the invention permits a reliable and reproducible PCR detection of mycobacteria.
- the invention describes for the first time the important influence of sample size on capture efficiency.
- the inventors have shown that a volume of 5 ml was optimal to capture Mycobacteria with the highest efficiency.
- the inventors showed that the manner of incubation influences in strong manner the capture efficiency.
- a non-covalent fixation via covalent attached protein A was optimal.
- the example presented herein below describes a new method with optimised steps resulting in superior efficiency of Mycobacterial capture, thus enhancing the sensitivity of downstream detection procedures.
- Dynabeads® M-450 Tosylactivated Hydrophobic naked beads with p- toluenesulphonyl (tosyl) reactive groups.
- Tosyl Hydrophobic naked beads with p- toluenesulphonyl (tosyl) reactive groups.
- Proteins are absorbed hydrophobically on initial coupling with covalent binding of primary amine groups (NH 2 and sulphydryl groups (SH)) occurring overnight. Coupling reactions can be performed at neutral pH although high pH and incubation at 37°C will promote covalent binding.
- Dynabeads® M-280 Tosylactivated Hydrophobic, monodisperse magnetic particles (2.8 ⁇ m in diameter) with p-toluene-sulfonyl (tosyl) groups, further surface activation not required. Allows easy coupling of antibodies with optimal orientation for affinity purification of proteins. Covalent coupling to primary amino- or sulphydryl groups in proteins/peptides. Coupling overnight at temperatures up to 37°C and pH 8-9.
- M. abscessus is grown to a density of McF1 (2.10 8 mycobacteria/ml) (Manual of Clinical Microbiology, Balows et al., 5 e e ⁇ , 1991) (3 to 4 days) at 37°C on rotary shaker
- Washed Pellet is suspended in a 15ml Greiner Tube with 5 ml IxPBS supplemented with 0.1% CHAPS and 0.1% Triton X-100
- HSPF3 ⁇ '-ATCGCCAAGGAGATCGAGCT-S' TM 6O 0 C (SEQ ID NO :3)
- HSPR4 5'-AAggTgCCg Cgg ATC TTg TT-3' TM 60 0 C (SEQ ID NO :4)
- hspSHf ⁇ '-CTGGTCAAGGAAGGTCTGCG-S' (SEQ ID NO :5)
- hspSHr ⁇ '-GATGACACCCTCGTTGCCAAC-S' (SEQ ID NO:6) (228 bp)
- the Mycobacteria For a rapid and precise analysis on their presence in samples, it is preferable to separate the Mycobacteria from the sample matrix and to concentrate the bacteria present in a very small volume. This enables a downstream processing of the sample for an analysis with molecular or immunological methods.
- the inventors have determined a procedure to efficiently isolate the Mycobacterial strains in environmental water-samples like tap-water or untreated water-samples.
- the concentration of bacteria with magnetic beads is used regularly in microbiological applications, like in the detection of Salmonella or E.coli, but most of the studies published so far have not driven by the interest to capture very low amounts of bacteria, since, in most of the cases, a pre-amplification phase is included or the initial number of bacteria is already very high (>1000 cfu/ml). When considering the studies published so far, capture-efficiencies below 50% of the total bacteria present in the sample have been reported (Fu et al., 2005; Yu ef a/., 2001).
- the present method of the invention was able to capture over 75% of 1.10 7 cfu (1E07 cfu) M. abscessus in a test volume of 0.5ml.
- the incubation was performed at room-temperature on a rocking platform in slow- motion to prevent the settling of the beads during the two hour incubation period.
- the inventors showed that this process is only efficient for high concentration of bacteria in the sample.
- Figure 2 indicates the efficacy of capture for low numbers of bacteria dropped to around 20% of the initial bacteria present in the spiked sample. This result indicated that the conventionally used incubation method is insufficient to ensure an efficient capture.
- the inventors showed that the capture of different concentrations of Mycobacteria in sample volume of 5ml can be performed with a consistent efficiency over 75% when using a 360° rotor in slow tilt rotation (2 rpm) and the 15ml tubes fixed in a 45° angle (see Figures 4 and 11).
- the detection method of the present invention was able to capture and concentrate Mycobacteria in different concentrations in a very efficient manner.
- the application of this detection method or capture procedure showed a 100-fold increase in sensitivity through bead-capture in comparison to a concentration of the bacteria through centrifugation (Figure 5).
- the inventors report the development and optimisation of different parts of a fast test-procedure to detect the presence of Mycobacteria in water-samples.
- the test is based on the non-specific and specific concentration of Mycobacteria in combination with a direct PCR-reaction.
- the inventors worked on three different components of the test: 1) the non-specific concentration of bacteria through filtration of 500 to 1000 ml water samples and their detachment, 2) The immunomagnetic concentration of Mycobacteria and 3) genomic DNA preparation and genus-specific PCR to detect the presence of captured Mycobacteria ( Figure 6).
- the detection of the bead-captured Mycobacteria is performed through a direct PCR-procedure. After a genomic DNA preparation adapted on low numbers of gram-positive bacteria, a genus-specific PCR detects the presence of Mycobacteria in the sample. In comparison to a non-specific concentration of the sample through centrifugation, the specific immunomagnetic capture was shown to be 500-fold more sensitive ( Figure 5).
- the developed test-procedure was validated against a set of different water-samples (Table 2). The inventors showed that all samples with a Mycobacterial count over than 50 cfu were correctly identified through the developed procedure of the present invention.
- PMA propidium-mono-azide
- Steps 1 and 2 Sample pre-concentration through filtration
- the spiked samples were filtrated through a 0.45 ⁇ m lsopore filter membrane (Millipore) on a Sartorius filtration-ramp using sterile plastic funnels.
- the filter with the bacteria was transferred sterile into a 50ml Greiner tube with 5ml of sterile detachment buffer (IxPBS supplemented with 0.01% Triton X-100).
- IxPBS sterile detachment buffer
- the fixed tube was vortexed at highest speed for 5 minutes.
- the supernatant with the detached bacteria was transferred into a 15ml Greiner tube.
- Step 3a Preparation of antibody-coated micro-beads
- the beads for the immunocapture were prepared as follows: 1ml of 2.8 ⁇ m tosylactivated micro beads (2x10 9 ; Dynal, Invitrogen) were washed in sterile IxPBS. After the addition of 500 ⁇ l IxPBS supplemented with recombinant ProteinA (Sigma P7837) to a final concentration of 1mg/ml, the tube was incubated over night at 37°C under slow rotation to prevent the settlement of beads to allow a covalent attachment of the ProteinA-molecule on the tosylactivated surface. The incubation was followed by a wash with IxPBS.
- the ProteinA-coated beads were incubated with a purified IgG fraction of the antiserum 35111 dissolved in 500 ⁇ l of IxPBS at a concentration of 1mg/ml. After 1 hour slow-tilt rotation at room-temperature the beads were used for the immunocapture procedure.
- Step 3b The immunocapture of Mycobacteria
- 25 ⁇ l (5x10 7 ) of the antibody-coated magnetic beads were added to 15ml Greiner tubes with the detached bacteria in buffer. The tubes were rotated slowly for 45 minutes at room-temperature. After the incubation, the beads with the attached bacteria were recuperated with a magnetic stand (Dynal, Invitrogen). After removal of the supernatant the beads were solubilised in 950 ⁇ l of phosphate buffer (FastDNA Spin for soil kit, MP Biomedicals) supplemented with Blue-Dextran (Sigma D4772) in a final concentration of 1pg/ ⁇ l.
- phosphate buffer FestDNA Spin for soil kit, MP Biomedicals
- Blue-Dextran Sigma D4772
- Step 4 The preparation of genomic DNA
- the bead-captured bacteria in phosphate buffer were transferred into screw- cap tubes supplemented with a mixture of beads in different sizes optimised for the mechanical disruption of bacteria in earth and water samples (Fast DNA spin KitTM). After the addition of lysis buffer from the kit, the tubes were beaten for 90 seconds in a "bead beater”TM (Biospec Products, USA) at highest frequency.
- the preparation of genomic DNA from the disrupted bacteria was performed according to the protocol.
- the isolated genomic DNA was eluted in a final volume of 50 ⁇ l water molecular biology grad (Gibco).
- Step 5 The quantitative PCR To detect and quantify the total mycobacterial charge of the sample, the inventors performed a PCR-assay targeting the superoxide dismutase A-gene (sodA) in the genomic DNA from Mycobacteria. sodA is a highly conserved housekeeping gene of Mycobacteria. Based on public available sequence information, the inventors identified a short variable stretch surrounded by two highly conserved regions (Position 484-510 and 670-700 on the M. avium sodA-gene (EMBL AccNr. AF180816).
- sodA superoxide dismutase A-gene
- the inventors designed a primer pair, SEQ ID NO: 11 and SEQ ID NO: 12, showing 100% identity with the Mycobacteria most frequently found in environmental water samples (M. avium , M. gordonae, M. kansasii, M. xenopi and M. abscessus).
- the quantitative PCR-reactions were performed on a Roche Lightcycler Instrument using a 384-well plate. The reactions were performed in a 10 ⁇ l volume.
- the PCR-mix consisted of 2 ⁇ l DNA, 0.05 ⁇ l of each primer (100 ⁇ M concentration), 5 ⁇ l Roche Sybergreen PCR Master Mix 2x and 2.9 ⁇ l water.
- the PCR reaction was divided into three phases: 1) a 5 minute activation at 95°C, 2) the amplification: denaturation for 15 seconds at 95°C, annealing for 15 seconds at 56°C and polymerisation for 30 sec at 72°C for 45 cycles and 3) the melting-temperature analysis of the obtained products to analyse the specifity of the amplicons.
- Each assay included a negative contamination control consisting of PCR-grade water treated in the same manner as the samples.
- the q PCR-reactions of the samples were performed in duplicate. To ensure a standardised analysis of the data, the inventors used the automated algorithms of the Roche Lightcycler analysis-software using the second derivative maximum method. Ct-values, slope and PCR efficiency were estimated.
- the values for the sensitivity were expressed as numbers of genomes per reaction.
- the inventors calculated the average weight for a standard mycobacterial genome as 5.5 femtogram from available mycobacterial complete genome-sequences ⁇ Mycobacterium tuberculosis (strains H37Rv and CDC1551), M. bovis AF2122/97, M. avium subsp. paratuberculosis K10, M. leprae TN, and M.
- EXAMPLE 3 qPCR lmmunocapture of Mycobacteria in water-samples: a rapid and sensitive method for routine testing
- Mycobacteria The genus Mycobacteria consists of over 150 species with different pathogenicity for humans. Besides the obligate pathogens M. leprae and the Mycobacterium tuberculosis group, potentially pathogenic Mycobacteria for humans and animals are the M. awt/m-complex and the environmental or atypical Mycobacteria.
- EM are responsible for non-tuberculosis infections in patients with AIDS and elderly persons. EM are also the source of infections in medical facilities due to inattentive treatment of sterile instruments during treatments. The exposure to EM through tap-water could be the source of EM-infections in humans as their presence in drinking water and in bio-films of water distribution systems was demonstrated.
- Routine testing in water microbiology laboratories through conventional culture-based methods are rarely performed as the slow growth-rates of EM make these procedures a time-consuming and laborious task.
- the inventors developed a fast (6 hours) and sensitive ( ⁇ 100 genomes per liter) test-procedure to detect the presence of non-tuberculosis Mycobacteria in water-samples.
- the test is based on a non-specific and a specific immunomagnetic concentration of the Mycobacteria present in the sample followed by a direct quantitative PCR-analysis (qPCR).
- the inventors worked on three different components of the test: (1) the non-specific concentration of bacteria through filtration of 500 to 1000 ml water samples and their detachment; (2) the immunomagnetic concentration of mycobacteria and (3) the genomic DNA preparation and genus-specific PCR to detect and quantify the mycobacterial content in the sample.
- the volume used for the capture procedure is important. Using constant concentration of beads and bacteria with different assay volumes, the inventors showed that 5 ml is optimal (Example 1).
- the capture efficiency of the Mycobacteria was always between 75 to 90% even at very low concentrations of mycobacteria (Example 1).
- the detection and quantification of the bead-captured Mycobacteria is performed through a quantitative PCR-assay (qPCR). After a genomic DNA isolation adapted on the low numbers of gram-positive bacteria present in a sample, a genus-specific PCR detects the presence of mycobacteria in the sample.
- qPCR quantitative PCR-assay
- the inventors developed a mycobacteria genus-specific PCR assay using the mycobacterial household gene sodA ( Figure 12).
- the inventors showed that the qPCR assay has the same PCR-efficiency for the set of the most important EM in water (M. kansasii, M. xenopi, M. avium, M. gordonae and M. abscessus) (Figure 13).
- Further experiments with the whole mycobacterial collection of the lnstitut Pasteur showed that nearly all mycobacterial DNA- templates (95 of 102) showed a positive result in the assay.
- the closest genus Rhodococus was negative (Table 3).
- the assay has an absolute sensitivity of 10 femtog ram/reaction (the equivalent of two mycobacterial genomes) and is linear over a range of 5 log.
- the inventors used the developed immunocapture qPCR to estimate the number of genomes in tap water samples from the lie de France region. (Figure 17). In this ongoing examination, the number of mycobacterial genomes in positive samples was between 100 and 10000 genomes per liter.
- the inventors analysed four different types of water-samples: 1) domestic and environmental water samples (10 samples), 2) water from the water works before and after treatment (10 samples in total), 3) the bacterial content of water-filters after the statutory time of utilisation (6 samples) and 4) samples from the formation of biofilms in an experimental set-up (4 samples).
- Each of the samples was divided into two fractions and independently analysed 1) via immunomagnetic capture and direct PCR for Mycobacteria and 2) through disinfection of the sample with 0,001% cpc (v/v) to eliminate background bacterial flora, filtration through a 0,45 ⁇ M polycarbonate membrane and its culture on 7H11 ODAC-agar for 5 weeks.
- the sodA qPCR assay ( Figures 12 and 13) was performed with 2 ⁇ l of genomic DNA (1 ng/ ⁇ l) prepared from the lnstitut Pasteur collection of Mycobacteria.
- a qPCR reaction was regarded as positive when a cp-value below 35 was obtained and when the melting temperature of the obtained PCR product could be clearly estimated. In some cases, two products with different melting temperature may be obtained (product I and product II). Note the negative signal obtained with Rhodococcus species, the closest bacterial genus to mycobacteria.
- Table 4 presents the identified Mycobacterial species in the samples together with the corresponding restriction patterns identified from the gel shown in Figures 18A and B.
- the table shows also the comparison of the estimated genome numbers with the parallel obtained cfu-values for the cultivated Mycobacteria after decontamination of the sample.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La présente invention concerne le domaine des mycobactéries, et plus spécifiquement un procédé d'isolement efficace et sélectif de mycobactéries, qui permet l'application d'outils pour la détection et l'identification de mycobactéries. Le procédé de l'invention peut être appliqué à des mycobactéries non tuberculeuses, également dénommées mycobactéries environnementales. La détection et l'identification d'une ou plusieurs souches de mycobactéries non tuberculeuses peuvent être ensuite réalisées.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA 2585670 CA2585670A1 (fr) | 2007-04-19 | 2007-04-19 | Methode de detection des mycobacteries non tuberculeuses |
CA002618289A CA2618289A1 (fr) | 2007-04-19 | 2008-01-21 | Methode de detection des mycobacteries non tuberculeuses |
PCT/IB2008/001255 WO2008129419A2 (fr) | 2007-04-19 | 2008-04-21 | Procédé de détection et/ou d'isolement de mycobactéries |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2145017A2 true EP2145017A2 (fr) | 2010-01-20 |
Family
ID=39720352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08750988A Withdrawn EP2145017A2 (fr) | 2007-04-19 | 2008-04-21 | Procédé de détection et/ou d'isolement de mycobactéries |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2145017A2 (fr) |
CA (2) | CA2618289A1 (fr) |
WO (1) | WO2008129419A2 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2270202A1 (fr) * | 2009-07-03 | 2011-01-05 | John Ikonomopoulos | Détection mycobactérienne |
EP2629095A1 (fr) * | 2012-02-17 | 2013-08-21 | Biosure R & T Cell Co. | Détection de cibles de protéine mycobactérienne incluant des points Quantum et séparation immunomagnétique |
PL3052650T3 (pl) | 2013-10-01 | 2019-09-30 | The University Of Nottingham | Wykrywanie mykobakterii za pomocą bakteriofagów |
WO2017077999A1 (fr) * | 2015-11-06 | 2017-05-11 | 公立大学法人横浜市立大学 | Procédé de détection d'adn dérivé du complexe tuberculosis |
CN106290864A (zh) * | 2016-08-12 | 2017-01-04 | 江苏泽成生物技术有限公司 | 一种人类免疫缺陷病毒抗原及抗体测定试剂盒及制备方法 |
CN109468316B (zh) * | 2018-12-10 | 2020-06-05 | 上海市肺科医院 | 一种基因序列组合物及其在制备分枝杆菌肺病检测试剂盒中的应用 |
CN112574885A (zh) * | 2019-09-29 | 2021-03-30 | 广东体必康生物科技有限公司 | 一种基于磁珠富集痰液样本的结核分枝杆菌检测方法及其专用试剂盒 |
CN116837119A (zh) * | 2022-03-25 | 2023-10-03 | 湖州申科生物技术股份有限公司 | 检测分枝杆菌dna的引物及检测方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0592894T3 (da) * | 1992-10-13 | 2001-08-06 | Hoffmann La Roche | Oligonukleotider afledt af SOD-familien |
AT501194A1 (de) * | 2004-12-30 | 2006-07-15 | Thomas Dr Schlederer | Verfahren zur isolierung von zellen und viren |
FR2890978B1 (fr) * | 2005-09-20 | 2012-08-17 | Hospices Civils Lyon | Procede de detection, dans un echantillon biologique de mycobacteries, et en particulier de mycobacteries caracteristiques de la tuberculose. |
-
2008
- 2008-01-21 CA CA002618289A patent/CA2618289A1/fr not_active Abandoned
- 2008-04-18 CA CA002629465A patent/CA2629465A1/fr not_active Abandoned
- 2008-04-21 EP EP08750988A patent/EP2145017A2/fr not_active Withdrawn
- 2008-04-21 WO PCT/IB2008/001255 patent/WO2008129419A2/fr active Application Filing
Non-Patent Citations (1)
Title |
---|
See references of WO2008129419A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2008129419A3 (fr) | 2009-04-30 |
CA2618289A1 (fr) | 2008-10-19 |
CA2629465A1 (fr) | 2008-10-19 |
WO2008129419A2 (fr) | 2008-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Honore-Bouakline et al. | Rapid diagnosis of extrapulmonary tuberculosis by PCR: impact of sample preparation and DNA extraction | |
Miller et al. | Evaluation of Gen-Probe Amplified Mycobacterium Tuberculosis Direct Test and PCR for direct detection of Mycobacterium tuberculosis in clinical specimens | |
Wards et al. | Detection of Mycobacterium bovis in tissues by polymerase chain reaction | |
Stanley et al. | Development of a new, combined rapid method using phage and PCR for detection and identification of viable Mycobacterium paratuberculosis bacteria within 48 hours | |
Fox et al. | Identification of Brucella by ribosomal-spacer-region PCR and differentiation of Brucella canis from other Brucella spp. pathogenic for humans by carbohydrate profiles | |
WO2008129419A2 (fr) | Procédé de détection et/ou d'isolement de mycobactéries | |
Neonakis et al. | Use of loop-mediated isothermal amplification of DNA for the rapid detection of Mycobacterium tuberculosis in clinical specimens | |
Modi et al. | Multitargeted loop-mediated isothermal amplification for rapid diagnosis of tuberculous meningitis | |
Stauffer et al. | Genus level identification of mycobacteria from clinical specimens by using an easy-to-handle Mycobacterium-specific PCR assay | |
Bi et al. | A rapid loop-mediated isothermal amplification assay targeting hspX for the detection of Mycobacterium tuberculosis complex | |
Alli et al. | Direct molecular detection of Mycobacterium tuberculosis complex from clinical samples–An adjunct to cultural method of laboratory diagnosis of tuberculosis | |
Chikamatsu et al. | Comparative evaluation of three immunochromatographic identification tests for culture confirmation of Mycobacterium tuberculosis complex | |
Lim et al. | Multicenter evaluation of Seegene Anyplex TB PCR for the detection of Mycobacterium tuberculosis in respiratory specimens | |
AU2005217124A1 (en) | Method for detecting a microorganism in a fecal specimen | |
van Coppenraet et al. | Mycobacterium haemophilum and lymphadenitis in children | |
Shah et al. | Development of a sensitive PCR-dot blot assay to supplement serological tests for diagnosing Lyme disease | |
Phetsuksiri et al. | Comparison of loop-mediated isothermal amplification, microscopy, culture, and PCR for diagnosis of pulmonary tuberculosis | |
Hosseiniporgham et al. | A rapid phage assay for detection of viable Mycobacterium avium subsp. paratuberculosis in milk | |
Weir et al. | Detection of Legionella by PCR in respiratory specimens using a commercially available kit | |
Tabibnejad et al. | The optimization of molecular detection of clinical isolates of Brucella in blood cultures by eryD transcriptase gene for confirmation of culture-negative samples | |
Abdeldaim et al. | Duplex detection of the Mycobacterium tuberculosis complex and medically important non‐tuberculosis mycobacteria by real‐time PCR based on the rnpB gene | |
Yousef | Detection of bacterial pathogens in different matrices: Current practices and challenges | |
Restrepo et al. | Selective enrichment and detection of mycobacterial DNA in paucibacillary specimens | |
CN116479150A (zh) | 单管一步法RPA-Cas12a/Cas13a快速检测耐甲氧西林金黄色葡萄球菌 | |
Munir et al. | Diagnosis of tuberculosis: molecular versus conventional method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20091117 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
17Q | First examination report despatched |
Effective date: 20100217 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20111101 |